Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Oilatum is a prominent dermatological brand specializing in the treatment and management of dry skin conditions, eczema, and atopic dermatitis. The brand offers a comprehensive range of therapeutic products, including bath emollients, moisturizing creams, and cleansers designed to rehydrate the skin and support its natural protective barrier. Originally developed by Stiefel Laboratories, Oilatum was acquired by GSK in 2009 and later sold to STADA Arzneimittel AG in 2019 as part of a strategic divestment of consumer healthcare brands. The product line is particularly well-regarded for its Oilatum Junior series, which is specifically formulated for the sensitive skin of infants and children. Oilatum products are clinically proven and widely recommended by healthcare professionals and pharmacists across Europe and international markets. Currently managed under STADA's Thornton & Ross subsidiary, the brand remains a leader in the over-the-counter dermatology sector.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Oilatum.